Anemia is a significant co-morbidity in patients with heart failure (HF) irrespective of the ejection fraction and is routinely quantified by hemoglobin concentration. Hemodilution as a cause of anemia has been described in systolic HF. The aim of this study was to further investigate the effects of plasma volume in patients with HF by (1) assessing the prevalence of dilutional anemia in patients with anemia and preserved ejection fractions and (2) exploring the relation between hemoglobin and red cell volume in these patients. Forty-six patients with anemia (as determined by standard hemoglobin measurement), 22 with HF and low ejection fractions (HFLEF) and 24 with HF and preserved ejection fractions (HFPEF), all underwent plasma volume measurement with iodine-131-labeled albumin. Hemoglobin values did not differ between subjects with HFLEF and those with HFPEF (10.8 ؎ 1.0 vs 11.0 ؎ 1.0 g/dl, p ‫؍‬ 0.55), but a red cell deficit was found in 88% of patients with HFPEF compared with 59% of those with HFLEF (p ‫؍‬ 0.04). This was the result of a higher prevalence of an expansion of plasma volume in patients with HFLEF (100%) compared with those with HFPEF (71%). Among all patients, no correlation was found between hemoglobin and red cell volume (r ‫؍‬ 0.09, p ‫؍‬ 0.54), but a correlation did exist in patients with normal blood volumes (r ‫؍‬ 0.55, p ‫؍‬ 0.02). In conclusion, dilutional anemia caused by an expansion in plasma volume without a red cell deficit occurs more commonly in patients with HFLEF than those with HFPEF, and hemoglobin does not correlate with red cell volume in patients with anemia and HF.
The cause of anemia in patients with heart failure (HF) is multifactorial, [1] [2] [3] and several therapies have been used with varying success. 2 Although hemoglobin values are typically used to diagnose anemia, low hemoglobin, on a physiologic basis, can be the result of either (1) a true red cell deficit or (2) hemodilution with plasma volume expansion. 4 Although hemoglobin or hematocrit provides a good estimate of red cell volume in healthy patients, 5 discordance between hemoglobin and red cell volume has been described in patients with polycythemia vera 6 and liver disease 7, 8 and in the presence of splenomegaly 9 due to the confounding effects of alterations in plasma volume. 5,9 -11 In patients with advanced HF and low ejection fractions (EFs), almost half were reported to have anemia on the basis of hemodilution with normal red cell volumes. 4 Whether a similar percentage of patients with HF and preserved EFs (HFPEF) have such dilutional anemia is unclear. Given the mixed success in treatment of anemia, 2, 12 issues surrounding the measurement of anemia deserve clarification. Accordingly, the purpose of this study was twofold: (1) to explore the correlation between hemoglobin values and red cell volume in patients with anemia and HF and (2) to determine whether patients with anemia and HFPEF have a similar prevalence of dilutional anemia as patients with HF with low EFs (HFLEF).
Methods
Subjects were outpatients referred for evaluation and treatment to the Columbia University Medical Center Heart Failure Center. Subjects aged Ͼ21 years with HF for Ն3 months' duration with stable symptoms were enrolled. All subjects had anemia (per the World Health Organization criteria: hemoglobin Ͻ13.0 g/dl in men and Ͻ12.0 g/dl in women). 2 Criteria for exclusion were acute decompensated HF, severe renal dysfunction (serum creatinine Ͼ3.5 mg/dl or history of nephrotic syndrome), and severe hepatic dysfunction (serum liver enzymes Ͼ3 times the upper limits of normal or history of cirrhosis). Cardiac medications included diuretics, digoxin, renin-angiotensin system inhibitors, and/or ␤-adrenergic receptor antagonists that were stable before the measurement of blood volume.
Forty-six nonedematous ambulatory patients with HF were studied: 24 with HFPEF and 22 with HFLEF. Subjects with HF were dichotomized into those with HFLEF and those with HFPEF by EFs of Ͻ45% or Ն45%; thus, patients with HFLEF had systolic HF. Blood volume measurements 4, 13, 14 and the degree of hemodilution in subjects with HFLEF have been reported previously 4 ; however, none of the previous analyses included populations of patients with HFPEF, and none focused on the relation between blood volume components and hemoglobin, as presented herein. The Institutional Review Board at Columbia University Medical Center approved the protocol. All subjects gave written informed consent before participation.
Plasma volume was determined after the intravenous administration of iodine-131-labeled albumin, as has been described previously. 4, 13, 15 Blood volume and red blood cell volume were calculated from the plasma volume measurement, the measured hematocrit corrected for trapped plasma, and mean body hematocrit and then compared with normal values for age, gender, height, and weight on the basis of the ideal weight system. 16 In addition to reporting absolute values, we report percentage deviation from expected values on the basis of the ideal weight system. Normovolemia was prospectively defined as a measured blood volume within 8% of the predicted normal value, and hypervolemia and hypovolemia were defined as blood volumes Ͼ8% and Ͻ8% of the predicted value, respectively. 4 True anemia was defined as having Ͻ95% predicted red blood cell volume on the basis of the study participant's gender and body size. 4 Hemoglobin was measured as part of a routine complete blood count from the hospital core laboratory (Sysmex XE 2100; Sysmex Corporation, Kobe, Japan).
Data are expressed as mean Ϯ SD, unless otherwise noted. Dichotomous variables were compared using chisquare analysis with Fisher's exact test when appropriate, and continuous variables were compared using unpaired 2-tailed Students' t tests. Simple linear regression analysis was used to determine the correlation between hemoglobin and red blood cell volumes. A p value Ͻ0.05 was considered significant. SAS version 9.1 (SAS Institute Inc., Cary, North Carolina) was used for all analyses.
Results
The demographic characteristics of the patient populations are listed in Table 1 . Subjects with HFLEF were predominately male, whereas those with HFPEF were older and predominately female. The groups did not differ with regard to body size, functional state (New York Heart Association class), renal function, and hemoglobin, but the patients with HFLEF were taking higher daily doses of loop diuretics.
Despite similar mean hemoglobin values, blood volume measurements differed between patients with HFLEF and those with HFPEF (Table 2) . With respect to blood volume, of the patients with HFPEF, 38% were hypovolemic, 42% were normovolemic, and 20% were hypervolemic. Of the patients with HFLEF, none were hypovolemic, 36% were normovolemic, and 64% were hypervolemic.
Plasma volume excess was found more frequently in the group with HFLEF (100%) than in the HFPEF group (71%), and the average plasma volume excess was significantly larger in the HFLEF group (p Ͻ0.001). Red blood cell deficit was more pronounced in patients with HFPEF, and plasma volume expansion was less pronounced in comparison with the HFLEF cohort. The incidence of dilutional anemia was 41% in the HFLEF group and 12% in the HFPEF group (p ϭ 0.04).
Among all patients with HF studied, there was no significant association found between hemoglobin and percent- Figure 1 ). However, when subjects were classified by volume status, normovolemic patients had a stronger association between hemoglobin and red cell volume (r ϭ 0.55, p ϭ 0.02) than either hypovolemic or hypervolemic patients, who had a nonsignificant association (r ϭ 0.016, p ϭ 0.97, and r ϭ 0.067, p ϭ 0.79, respectively; Figure 1 ).
Discussion
The principal findings of this study are twofold. First, in subjects with anemia and HF, the prevalence of a red cell deficit differs between patients with normal compared with reduced EFs. Specifically, most subjects with HFPEF (88% in this series) had red cell deficits, whereas slightly more than half of subjects with HFLEF had red cell deficits. Second, the correlation of hemoglobin, the standard measure by which clinicians diagnose and manage anemia in patients with HF, with red cell volume is poor irrespective of the EF. This is because of the confounding effects of alterations in plasma volume, which are common in patients with HF, caused by either the underlying disease or the concomitant use of diuretic therapy. Blood volumes in patients with HF have been evaluated in multiple studies in patients with HFLEF, with alterations of blood volume contraction and expansion described. 13, 14 Blood volumes have not been described in patients with HFPEF, and our findings suggest that patients with compensated HFPEF can likewise be hypovolemic, normovolemic, or hypervolemic.
The discordance between hemoglobin and red cell volume found in this study is in accordance with research from other patient populations, in which the poor association has been attributed to alterations in plasma volume. 5,9 -11 Much of the previous research in this area has been focused on polycythemia vera, in which plasma volume derangements and splenomegaly confound the utility of using hemoglobin (or hematocrit) as a surrogate for red cell volume. 9 Splenomegaly 17, 18 and plasma volume expansion 13 have been described in patients with HF. Given the relevance of plasma volume to the relation between hemoglobin and red cell volume, some have noted that hematocrit (or hemoglobin) is no more a marker of red cell volume than serum sodium is of total body sodium. 9 Our data support this explanation; the association between hemoglobin and red cell volume was stronger in normovolemic patients than in those with hypovolemia or hypervolemia. Plasma volume alterations, whether leading to hemodilution or hemoconcentration, therefore appear to influence hemoglobin determination.
These observations may have implications for the treatment of anemia in patients with HF. Two main therapies have been used to treat anemia in patients with HF, intravenous iron 19, 20 and erythropoietic stimulators, 21 either alone or in combination, 22, 23 and data on treatment have been mixed. 2, 12 The 2 therapies have been shown in small single-center studies to increase hemoglobin, quality of life, and exercise tolerance in patients with anemia and HF with systolic dysfunction. 21, [23] [24] [25] [26] However, a larger multicenter study, the Study of Anemia in Heart Failure-Heart Failure Normovolemia is blood volume within 8% of the predicted normal value. Hypervolemia is blood volume Ͼ8% of the predicted normal value. Hypovolemia is blood volume Ͻ8% of the predicted normal value. Blood volume deviation refers to the percentage difference between the predicted normal value and the value determined by blood volume analysis.
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Heart Failure/Anemia in HFPEF Versus HFLEF Trial (STAMINA-HeFT), did not meet its primary end point of exercise time and quality-of-life changes. 27 Potential explanations for the discrepant results include that treatment for anemia in these trials may have been applied to subjects with dilutional anemia as well as to those with red cell deficits. In the only study in which blood volume was measured during erythropoietin treatment, 21 the limited data suggested that that erythropoietin may have direct effects on both components of total blood volume (red cell volume and plasma volume). Erythropoietin increased hemoglobin in patients with HF with true and dilutional anemia through different mechanisms; although the 2 groups had increases in red cell volume, the patients with dilutional anemia also experienced reductions in plasma volume. 21 Although the effects on plasma volume are poorly understood, they have been observed in dialysis patients as well. 28 Although erythropoietin may therefore benefit patients with HF with both normal and reduced red cell volumes, perhaps diuresis may be the safer and cheaper approach to patients with dilutional anemia, without predisposing patients to the side effects attributed to erythropoietin.
There are several limitations to our study. Our study population consisted of patients with advanced HF receiving care at a tertiary center, which may not represent the general HF population. All patients were stable outpatients receiving high-dose, long-term diuretic therapy; hence, the alterations of plasma volume observed need to be interpreted in this context, and the relevance of these measures to the pathophysiology of the acutely decompensated state is limited. Splenomegaly was not assessed in our patients. The data measurements, including hemoglobin and blood volume measurements, were taken at a single point in time. Blood volume measurements were done with iodine-131-labeled albumin, and we did not directly measure red cell volume. However, the validity of our approach for measuring red cell volume indirectly versus the chromium-labeling technique has been demonstrated, with only small differences found between chromium labeling and the albumin dilution technique. 29 
